Biologist Resurrects 3.2 Billion-Year-Old Enzyme: Discoveries in Ancient Biology | Science News

A groundbreaking research team from the University of Wisconsin-Madison has successfully reverse-engineered a primitive nitrogen-fixing enzyme. This discovery sheds light on how life thrived before the Earth was transformed by oxygen and establishes reliable chemical markers for detecting extraterrestrial life.



Resurrection and characterization of an ancestral nitrogenase. Image credit: Rucker et al., doi: 10.1038/s41467-025-67423-y.

Led by Professor Betül Kaçar, the research focuses on an essential enzyme known as nitrogenase, which plays a pivotal role in converting atmospheric nitrogen into bioavailable forms.

“We selected an enzyme that significantly influences life on Earth and investigated its evolutionary history,” Professor Kaçar stated.

“Without nitrogenase, the existence of modern life as we know it would be impossible.”

Traditionally, scientists have depended on geological evidence to reconstruct Earth’s historical life.

However, significant fossils and rock samples are scarce and often require fortuitous discovery.

Professor Kaçar and his team view synthetic biology as a valuable tool to bridge these gaps, allowing them to construct specific ancient enzyme reconstructions, insert these into microorganisms, and study them in contemporary lab settings.

“The Earth of 3 billion years ago was vastly different from the world we recognize today,” remarked Dr. Holly Rucker.

“Before the Great Oxidation Event, the atmosphere was rich in carbon dioxide and methane, and life predominantly consisted of anaerobic microorganisms.”

“Understanding how these microorganisms accessed vital nutrients like nitrogen enhances our comprehension of how life persisted and evolved before oxygen-dependent organisms began to alter the planet.”

“Though fossilized enzymes are unavailable for study, these enzymes can leave discernible isotopic traces, measurable in rock samples.”

“Much of the prior research assumed ancient enzymes produced isotopic signatures akin to modern enzymes,” added Dr. Rucker.

“This holds true for nitrogenase; the isotopic traces we observe from ancient times correspond with modern signatures, providing deeper insights into the enzyme itself.”

The researchers discovered that ancient nitrogenase enzymes, despite having different DNA sequences, maintain the same mechanisms for isotopic signatures observed in the rock record.

“As astrobiologists, our understanding of Earth helps us comprehend the potential for life elsewhere in the universe,” Professor Kaçar emphasized.

“The quest for life begins right here on our 4-billion-year-old planet.”

“To grasp future possibilities and life beyond our planet, we must first understand our own history.”

The results were published today in the online journal Nature Communications, accessible here.

_____

Rucker et al. 2026. The revived nitrogenase reproduces the standard N isotope biosignature spanning two billion years. Nat Commun 17,616; doi: 10.1038/s41467-025-67423-y

Source: www.sci.news

Study: Neanderthal-Inherited Genetic Mutations Decrease Major Muscle Enzyme Activity

An AMPD1 variant from Neanderthals reduces enzyme activity by 25% in lab-produced proteins and up to 80% in muscles of genetically modified mice. This variant is present in all sequenced Neanderthals but absent in other species. It entered the modern human gene pool through interbreeding approximately 50,000 years ago, leading to its presence in up to 8% of today’s Europeans.

Maccak et al. Research indicates that genetic variants inherited from Neanderthals impair essential enzyme functions in muscle performance. Image credit: Holger Neumann/Neanderthal Museum.

The enzyme AMPD1 is crucial for muscle energy production and overall muscle function.

A decrease in its activity due to genetic mutations is the leading cause of metabolic myopathy in Europeans, with a prevalence of 9-14%.

In a recent study led by Dr. Dominik Macak from the Max Planck Institute for Evolutionary Anthropology, researchers compared ancient Neanderthal DNA with modern human genomes.

They discovered that all Neanderthals have specific AMPD1 variants absent in other species.

Enzymes produced in the lab with this variant exhibited a 25% decrease in AMPD1 activity.

In genetically modified mice, this reduction in muscle tissue activity reached 80%, negatively affecting enzyme performance.

Moreover, the study shows that modern humans acquired this variant from Neanderthals who lived in Europe and Western Asia before interacting with modern humans around 50,000 years ago.

Currently, approximately 1-2% of non-African individuals carry Neanderthal DNA.

The Neanderthal AMPD1 variant is found in 2-8% of Europeans today, indicating general acceptance in the gene pool.

“Interestingly, most individuals with these variants do not face serious health concerns,” noted Dr. McCuck.

“However, enzymes seem to significantly influence athletic performance.”

Analysis of over 1,000 elite athletes across diverse sports showed that those with non-functional AMPD1 are less likely to reach the highest athletic levels.

“Having defective AMPD1 enzymes decreases the chances of achieving elite athletic ability by half,” Dr. McCuck said.

While AMPD1 activity appears to have moderate significance in contemporary Western societies, it becomes crucial under extreme physical conditions, such as those faced by athletes.

Researchers highlight the need for studying genetic variation within physiological and evolutionary contexts to grasp biological implications.

“Cultural and technological advancements in both modern humans and Neanderthals may have lessened the necessity for extreme muscle performance,” explains Dr. Hugo Zeberg, a researcher at the Max Planck Institute for Evolutionary Anthropology and Karolinska Institute.

“Understanding how current gene variants influence human physiology can yield valuable insights into health, performance, and genetic diversity.”

Survey results were published in the journal Natural Communication on July 10, 2025.

____

D. McCuck et al. 2025. Muscle AMPD1 exhibited reduced deaminase activity in Neanderthals compared to modern humans. Nat Commun 16, 6371; doi:10.1038/s41467-025-61605-4

Source: www.sci.news

Preventing Inflammation After Stroke by Blocking This Enzyme

Stroke can cause irreversible, life-altering, and long-term brain damage. A stroke can be caused by a blood clot called a thrombus. ischemic strokeor a ruptured blood vessel. hemorrhagic stroke. Our brains require large amounts of oxygen, so when blood flow is interrupted, oxygen-dependent brain substances are damaged in the short term.

Think of the blood vessels in your brain as a perfectly designed highway. When an ischemic stroke occurs, blood clots block these blood vessels, preventing oxygen from reaching the brain. When an ischemic stroke occurs, microglia It acts as our body's “ambulance” and focuses on the site of the blood clot. Scientists classify microglia into two types: anti-inflammatory and pro-inflammatory. Anti-inflammatory microglia help fight inflammation in the brain. Pro-inflammatory microglia cause further brain inflammation by damaging nerve cells. neuronremove the protective sheath known as . myelin.

Chinese researchers recently developed a hypothesis that inhibits an enzyme associated with inflammation called histone deacetylase 3 or HDAC3 may reduce proinflammatory microglial production in mice. They reasoned that because HDAC3 enzymes activate proinflammatory immune cells, inhibiting these enzymes may reduce inflammation.

To study how stroke affects the production of inflammatory cells, the researchers first determined which cell types in mice were most likely to be affected by HDAC3. They induced strokes in mice and found that HDAC3 was more active in the mice's microglia than in other cells. High levels of HDAC3 were present in the mice's neurons, but they were not active. The researchers interpreted this data to suggest that HDAC3 plays a more important role in microglia than in other types of brain cells.

Next, the researchers genetically engineered mice that lack microglial HDAC3. knockout mouse. They compared the knockout mice to a control group of mice that retained microglial HDAC3. They induced strokes in both groups of mice for 60 minutes. They then examined the mice's brains using MRI after three, 14, and 35 days to see how the brain damage caused by the stroke progressed in the two different groups. They found that the knockout mice had less brain damage than control mice on all three days.

The researchers also found that the knockout mice had better scores on motor, learning, memory, and behavioral tests than control mice. For example, when scientists applied sticky tape to the soles of mice's feet, the knockout mice removed the tape about 50 seconds faster than control mice. The knockout mice had less myelin loss and less degeneration of electrical pathways in the brain. The researchers interpreted these results to suggest that inhibiting microglial HDAC3 in mice prevented brain damage and improved mental performance after stroke.

The researchers also investigated which gene There were active and inactive forms in two sets of mice. They found that all pro-inflammatory genes tested were inactive in knockout mice, but highly active in mice with microglial HDAC3. They also found that the knockout mice had less activity in genes that produce inflammatory cells.

The researchers concluded that deleting microglial HDAC3 can prevent brain inflammation, myelin removal, and brain tissue damage during stroke. However, before HDAC3 deletion becomes a treatment, they recommended that future researchers determine whether there are any serious side effects. The reduction in inflammation in mice means the same technology could one day be used to reduce the inflammatory effects of stroke in humans.


Post views: 189

Source: sciworthy.com